724471-16-3Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS
-
Page/Page column 28, (2010/11/28)
The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.
Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia
Liu, Kun,Xu, Libo,Berger, Joel P.,MacNaul, Karen L.,Zhou, Gauchao,Doebber, Thomas W.,Forrest, Michael J.,Moller, David E.,Jones, A. Brian
, p. 2262 - 2265 (2007/10/03)
A series of 2-aryloxy-2-methyl-propionic acid compounds and related analogues were designed, synthesized, and evaluated for their PPAR agonist activities. 2-[(5,7-Dipropyl-3-trifluoromethyl)-benzisoxazol-6-yloxy]-2- methylpropionic acid (4) was identified
O-Arylmandelic acids as highly selective human PPAR α/γ agonists
Adams, Alan D.,Hu, Zao,Von Langen, Derek,Dadiz, Adonis,Elbrecht, Alex,MacNaul, Karen L.,Berger, Joel P.,Zhou, Gaochao,Doebber, Thomas W.,Meurer, Roger,Forrest, Michael J.,Moller, David E.,Jones, A. Brian
, p. 3185 - 3190 (2007/10/03)
A new class of O-arylmandelic acid PPAR agonists show excellent anti-hyperglycemic efficacy in a db/db mouse model of DM2. These PPARα-weighted agonists do not show the typical PPARγ associated side effects of BAT proliferation and cardiac hypertrophy in
